Premium
Wogonin inhibits WEHI‐3 leukemia cells in Blab/C mice In Vivo
Author(s) -
Tang NouYing,
Su ChinCheng,
Chen GuangWei,
Chung JingGung
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a806-c
Subject(s) - wogonin , in vivo , leukemia , in vitro , pharmacology , flow cytometry , apoptosis , mtt assay , chemistry , peripheral blood mononuclear cell , spleen , cell growth , medicine , cancer research , immunology , biology , biochemistry , pathology , traditional chinese medicine , scutellaria baicalensis , alternative medicine , microbiology and biotechnology
Wogonin is one of the flavonoids and it has been shown to exert antioxidant, anti‐viral, anti‐bacteria, anti‐thrombotic, anti‐inflammatory and cytostatic activities. Recently, it also has been reported that wogonin induced apoptosis of human leukemia cells. Importantly, wogonin lacks toxicity for normal peripheral blood mononuclear cells. However, there is no available information to address whether or not wogonin affects leukemia cells in vivo. In this study, we investigated the effects of wogonin in vivo affecting murine leukemia WEHI‐3 cells. This study is divided into in vitro and in vivo, the in vitro studies, it indicated that wogonin inhibit cell proliferation of WEHI‐3 using MTT assay and those effects are dose‐and time‐dependent manners. The in vivo studies, the major assay is flow cytometry and the results indicated wogonin inhibit the percentage of Mac‐3 marker, inhibiting the differentiation of precursor of macrophage and T cells; wogonin decrease the weights of liver and spleen after comparying to non‐treated groups; wogonin decreased the sizes of liver and spleen. The results indicated that wogonin affects WEHI‐3 cells in vitro and in vivo. Wogonin may be used for therapy of leukemia.